Skip to main content

ASND · Ascendis Pharma A/S · Metrics

Track ASND — free
$259.85 +3.03 (+1.18%) At close · Nov 9 Play latest call Q2 2026 earnings call transcript
Market Cap
$17.10B
Shares
65.80M
Volume · Nov 9 896.06K Avg daily vol (3M) 709.57K

ASND metrics

77 of 125 screener metrics currently available.

Open in screener

Market overview

2 metrics
Share price
$259.85
Market cap
$17.10B

Price action

23 metrics
Price change (1W)
+4.4%
Price change (30D)
+14.5%
Price change (3M)
+1.7%
Price change (6M)
+8.9%
Price change (YTD)
+21.9%
Price change (1Y)
+31.4%
Trailing year
Price change (5Y)
+63.7%
52-week high
$277.18
52-week low
$196.01
Change from 52-week high
-6.3%
Change from 52-week low
+32.6%
Annualized volatility
38.6%
Annualized volatility (3M)
36.5%
Implied volatility (30D)
47.1%
IV rank (1Y)
34.0
IV percentile (1Y)
52.0
Beta
0.4
RSI (14D)
67.3
Price vs SMA 50
+7.1%
Price vs SMA 200
+8.7%
Avg volume (3M)
709,572
Relative volume
1.3
Average dollar volume
$172.23M

Company

3 metrics
Sector
Healthcare
Industry
Biotechnology
Shares outstanding
65.80M

Valuation

12 metrics
P / E (TTM)
—
Trailing earnings
PEG ratio
—
EV / revenue
13.9×
reciprocal yield 7.2%
EV / EBITDA
—
EV / EBIT
54.9×
reciprocal yield 1.8%
P / sales
13.8×
reciprocal yield 7.2%
P / book
10.3
reciprocal yield 9.7%
FCF yield
—
TTM · current market cap
Buyback yield
0.7%
P / FCF
—
P / operating cash flow
41.6
reciprocal yield 2.4%
Earnings yield
—

Historical valuation

8 metrics
P / E historical average (3Y)
—
P / E historical average (5Y)
—
EV / revenue historical average (3Y)
—
EV / revenue historical average (5Y)
—
EV / EBIT historical average (3Y)
—
EV / EBIT historical average (5Y)
—
EV / EBITDA historical average (3Y)
—
EV / EBITDA historical average (5Y)
—

Dividends & buybacks

7 metrics
Dividend yield
—
Trailing 12 months
Payout ratio
—
Shareholder yield
0.7%
Dividend / share (TTM)
—
Dividend growth YoY
—
Dividend growth streak
—
Last ex-dividend
—

Earnings calendar

2 metrics
Next earnings
—
Last earnings
2026-08-13

Profitability

9 metrics
Gross margin
91.3%
Operating margin
25.4%
Trailing 12 months
Net margin
70.8%
Gross profit (TTM)
$955.89M
Operating profit (TTM)
$266.17M
Net income (TTM)
$866.82M
Trailing 12 months
Diluted EPS (TTM)
—
FCF margin
—
Effective tax rate
-658.2%

Per share

11 metrics
Revenue per diluted share (TTM)
—
Gross profit per diluted share (TTM)
—
Operating profit per diluted share (TTM)
—
EBITDA per diluted share (TTM)
—
Net income per diluted share (TTM)
—
Operating cash flow per diluted share (TTM)
—
Free cash flow per diluted share (TTM)
—
Capital expenditures per diluted share (TTM)
—
R&D per diluted share (TTM)
—
Stock compensation per diluted share (TTM)
—
Book value per share
$-2.63

Growth

11 metrics
Revenue growth YoY
+114.7%
Year over year
Net income growth YoY
—
Revenue (TTM)
$1.22B
Trailing 12 months
EPS growth YoY
—
Shares change YoY
+2.1%
Year over year · more shares
Revenue CAGR (3Y)
+141.4%
Revenue CAGR (5Y)
+153.0%
EPS CAGR (3Y)
—
EPS CAGR (5Y)
—
FCF CAGR (3Y)
—
FCF CAGR (5Y)
—

Quality

14 metrics
Return on equity
51.6%
Return on assets
32.4%
Debt / equity
—
Current ratio
3.0
EBITDA (TTM)
—
Free cash flow (TTM)
—
Quick ratio
2.3
Interest coverage
1.3
Net debt / EBITDA
—
Return on invested capital
—
Trailing 12 months
Net cash
−$122.31M
Latest balance sheet
Cash & equivalents
$927.36M
Total assets
$2.61B
Total debt
$845.30M

Cash flow & spend

7 metrics
Operating cash flow (TTM)
$406.57M
Capital expenditures (TTM)
$1.02M
R&D (TTM)
$326.49M
SG&A (TTM)
—
Stock compensation (TTM)
$140.63M
R&D / revenue
26.7%
Stock compensation / revenue
11.5%

Ownership (13F)

9 metrics
13F filers
317
13F filer change QoQ
+31
Institutional ownership
102.8%
Conviction holders (share of 13F filers)
4.4%
Crowding (high-turnover and private-fund holders)
—
Private-fund adviser ownership
—
Active holders' share change QoQ
+3.1%
Holder tenure
18.7
Price vs estimated holder cost
+52.4%

Ownership (registered funds)

1 metrics
Index-fund ownership
0.4%

Short interest

3 metrics
Short interest
4.8%
Latest settlement · 4.2 days to cover
Days to cover
4.2d
Short-squeeze score
60 / 100

Insider activity

2 metrics
Net insider buying (90D)
−$380,251
Insider-sentiment score
47 / 100

Risk flags

1 metrics
Going concern
—
Key facts CIK 1612042 CUSIP K08588103 13F (30d) 151 filings 129 filers Visit website Investor relations